Abbott Enrolls First U.S. Patient in Global EXCEL Trial Comparing XIENCE to Coronary Artery Bypass Surgery
Abbott’s EXCEL is the Largest Trial to Date Designed to Evaluate Optimal Treatment Strategy (Surgery or Stenting) in Patients with Unprotected Left Main Disease
Appeals court: Boston Scientific doesn’t infringe Cordis patent
UPDATED Sept. 30, 2011
Judge nixes J&J’s bid to sidestep a $482 million Cordis verdict
It’s been a tough stretch in the courtroom for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp.
The health care giant’s stent-making unit lost its bid for a new trial in the $482 million patent infringement lawsuit it lost to stent pioneer Dr. Bruce Saffran Tuesday.
That loss followed the failure of its bid to overturn a pair of U.S. Patent Office rules.
Stents Wars: Abbott’s Xience V stent drug coating beats Boston Scientific’s Taxus DES
Stent situation: a victory for coverage
A federal study of a new stent designed to prevent repeat strokes was stopped early because 2 1/2 times (14.7%) more people either died or had a repeat stroke after receiving the stent than those who received drugs and counseling (5.8%). The $20 million study, stopped after just 451 stroke victims had been enrolled because of the alarming trend in the results, was sponsored by the National Institute of Neurological Diseases and Stroke.
Sign up to get our free newsletters delivered right to your inbox.
Legal update: Cook vows to keep fighting in Endologix patent spat
While Endologix Inc. (NSDQ:ELGX) called an early decision in the patent battle against Cook Medical over abdominal aortic stent technology a victory, Cook officials responded that they have more cause to celebrate and that they aren’t done fighting yet.
SNN’s whistleblower, Abbott versus Boston Scientific, Covidien repurchases $2 billion in shares | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Stents: Abbott’s Xience DES bests Boston Scientific’s Taxus
Stent market goliath Abbott Laboratories’ (NYSE:ABT) Xience V drug-eluting stent proved safer and more effective in nondiabetic patients over DES market leader Boston Scientific Corp.’s (NYSE:BSX) Taxus.
Abbott’s Xience V is a everolimus-eluting stent while Taxus is a paclitaxel-eluting stent, and both are FDA-cleared for the U.S. market.